Charles River Laboratories Intl. Inc vs Kroger Co — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Kroger Co trades at $61.26 (market cap $36.27B). The key difference: Kroger Co is far larger — about 2.5× Charles River Laboratories Intl. Inc's market cap, and Kroger Co pays a 2.54% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Kroger Co for 108 Days on average.
| CRL | KR | |
|---|---|---|
Market Cap | $14.23B | $36.27B |
Volume | 1,176,885 | 8,301,523 |
Sector | Health | Consumer Staples |
52-Week High | $310.77 | $75.60 |
52-Week Low | $149.93 | $55.53 |
Typical Hold Time | 33 Days | 108 Days |
Enterprise Value | $17.06B | $57.69B |
Dividend Yield | — | 2.54% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Kroger (KR) trades at $59.25, up 1.44% with a bullish technical signal. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, supported by positive cash flow trends. Recent earnings beat expectations in two of the last three quarters, while analysts maintain a Moderate Buy consensus with a $70.62 price target. The company continues digital growth initiatives and maintains dividend payments.
Kroger presents a value opportunity with low P/S ratio (0.25) and consistent profitability, though near-term risks include integration challenges from acquisitions and softer sales guidance. The stock's current price near support at $58 offers potential upside to analyst targets, balanced by competitive pressures in the grocery sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →